Northway Biotech
24.5.2023 18:24:40 CEST | ACCESS Newswire | Press release
WALTHAM, MA / ACCESSWIRE / May 24, 2023 / Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), established in 2004, with an EMA and FDA-compliant, state-of-the-art cGMP manufacturing site in Vilnius, Lithuania, announced the completion of its expansion project for cGMP manufacturing facilities in Waltham, Massachusetts. This significant accomplishment further solidifies Northway Biotech's standing as an influential player in the global biopharmaceutical landscape.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.This recent growth is an extension of the successful launch of Northway Biotech's process and analytical development laboratories in Waltham (Greater Boston area) in 2020. The expanded facility now includes state-of-the-art cGMP suites, marking a significant milestone in the company's journey. The newly established cutting-edge biomanufacturing suites host a microbial fermentation train with up to 450 liters of volume capacity, and a mammalian production train with the ability to handle volumes of up to 2,000 liters. Northway Biotech has further established a specialized, fully automated fill and finish line to accommodate its clients' varied needs, supporting high-throughput filling into vials, syringes, and cartridges.
Prof. Vladas Algirdas Bumelis, CEO of Northway Biotech, shared his insights regarding this accomplishment, stating, "The addition of GMP suites in our US site represents a transformative step for our organization, enabling us to provide comprehensive end-to-end solutions from our second site now. We are poised to transition current process development projects into the cGMP manufacturing phase in a timely manner, in line with our clients' committed schedules. Additionally, our longstanding US partners who have engaged with our Lithuanian site can now also take advantage of the geographical convenience of our modern facilities located in the Greater Boston Area. With our fully functional and technologically advanced manufacturing site at our disposal, Northway Biotech is perfectly positioned to take on manufacturing projects aimed at both clinical and commercial supply."
To commemorate this significant expansion and express gratitude to its valued partners and industry leaders, Northway Biotech will be hosting a grand opening event for its cGMP suites on June 8. This event promises to be an occasion of celebration and networking, providing an opportunity for attendees to witness firsthand the state-of-the-art facilities and engage in meaningful discussions within the biotech community.
About Northway Biotech - https://www.northwaybiotech.com
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately-owned company founded in 2004 and located in Vilnius, Lithuania; London, United Kingdom; and Waltham, Massachusetts, United States.
For Further Information, Contact:
Prof. Vladas Algirdas Bumelis
CEO and Chairman of the Board
Northway Biotech
vladas.bumelis@northwaybiotech.com
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/757061/Northway-Biotech-Set-to-Launch-Advanced-Microbial-and-Mammalian-GMP-Facilities-in-Massachusetts
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
OMP Ranked in Highest Two Across All Four Use Cases in the 2026 Gartner(R) Critical Capabilities for Supply Chain Planning Solutions: Process Industries30.4.2026 15:00:00 CEST | Press release
ANTWERPEN, BE / ACCESS Newswire / April 30, 2026 / OMP, a leading provider of AI-powered supply chain planning, has been ranked in highest two across all four Use Cases in the 2026 Gartner® Critical Capabilities for Supply Chain Planning Solutions report for process industries. This report, a companion to the Gartner® Magic Quadrant™, evaluates 16 vendors on Critical Capabilities and real-world Use Cases, helping organizations assess how well solutions support different levels of supply chain planning maturity. This recognition follows OMP's recent position as highest in Ability to Execute and furthest in Completeness of Vision in the 2026 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions: Process Industries. Get the full Gartner® Critical Capabilities report. Consistent strength in real-world planning Use Cases The critical capabilities that most distinguish supply chain planning (SCP) vendors for process industries from each other in 2026 are AI-driven planning and decisio
Karbon-X Advances Sur del Meta REDD+ Project with Biodiversity Partnership30.4.2026 15:00:00 CEST | Press release
Collaboration supports the use of ecological data in project design as demand for high-integrity carbon credits accelerates. CALGARY, AB / ACCESS Newswire / April 30, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions provider operating across compliance and voluntary carbon markets, today announced the formalization of a strategic partnership with Fundación BioHerencia, a participating landowner of the REDD+ project Sur del Meta currently being implemented in Colombia. The partnership aims to embed biodiversity conservation within the REDD+ project by combining the landowner's conservation expertise with community-based monitoring efforts. The agreement establishes a technical, scientific, and operational framework to support the integration of field-based ecological data into the project's Measurement, Reporting, and Verification (MRV) systems. As a participating landowner within the REDD+ project, BioHerencia owns Harpy Eagle
Datavault AI and Kings Mine Capital Agree to Establish $150 Million+ GoldVault(TM) Tokenization Program30.4.2026 15:00:00 CEST | Press release
Agreement Contemplates Bullion at $3,000 an Ounce to Spot for 24-Month Delivery with $40 Million Projected Profit at $5000 an Ounce. GoldVault™ Tokens Issue at Discount to Spot with Production-Linked Royalty Stream PHILADELPHIA, PA / ACCESS Newswire / April 30, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, and King Mining Capital ("King Mining Capital") today announced that they have entered into a agreement for a multi-component strategic transaction that will combine a Datavault AI equity investment in King Mining Capital, a Datavault AI stock-funded purchase of 20,000 ounces of physical gold bullion, and the launch of a $150 million-plus GoldVault™ tokenization program backed by King Mining Capital's high-grade gold resources. Direct Equity, Physical Bullion, and Stock-Funded Consideration Subject to entering into a definitive agreem
doola Launches Agentic LLC Formation: Start a U.S. Company in Minutes Without Leaving Claude or Replit30.4.2026 14:00:00 CEST | Press release
Start a U.S. Company in Minutes Without Leaving Claude or Replit Founders can go from idea to LLC without ever leaving the tool they're building in doola is the first business formation platform to launch a Model Context Protocol (MCP) integration for LLC formation, enabling founders to start an LLC through a conversation directly in Claude or Replit. The flow takes minutes. No new browser. No context switching. Available to US and non-US founders and developers (no US SSN required). doola has helped more than 15,000 founders in 175+ countries start and scale US businesses, backed by $13M in venture capital from Y Combinator, HubSpot Ventures, Nexus Venture Partners, and other top investors. NEW YORK CITY, NY / ACCESS Newswire / April 30, 2026 / doola, the AI Business-in-a-Box™ for global entrepreneurs, today became the first business formation platform to enable native LLC formation within AI agents. With new MCP integrations for Claude and Replit, founders can now form a Wyoming LLC
GoodData is Now GoodData.AI, Reflecting Its AI-First Direction30.4.2026 11:00:00 CEST | Press release
The brand update marks the company's continued shift toward intelligence-driven analytics. SAN FRANCISCO, CA / ACCESS Newswire / April 30, 2026 / GoodData, the AI-native decision intelligence platform, today announced it is rebranding as GoodData.AI. The rebrand reflects a strategic direction GoodData has been building toward for several years. The platform has been developed around a core conviction: that governed, AI-native analytics is the foundation every serious enterprise needs. The semantic layer, context management, open architecture, composability, agentic frameworks, and analytics-as-code introduced over that period were each a step toward that foundation. "GoodData.AI is the name that reflects both where we've been and where the market is going," said Roman Stanek, CEO and Founder of GoodData.AI. "Enterprises need analytics that AI can operate, govern, and trust at scale. That's what we're built for, and we're moving faster than ever to get customers there." That pace is vis
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom